

IAP5 Rec'd PCT/PTO 26 JUL 2006  
10/587841

"Express Mail" Label No. EV 543777904 US  
Date of Deposit July 26, 2006

PATENT

Attorney Docket No.: 082368-008600US

Client Ref. No.: M3-A0307P-US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Amendment  
Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

By: 

Aaron Hokamura

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Tomoko NAKAGAWA et al.

Application No.:

Filed:

Int'l Application No.: PCT/JP05/00923

Int'l Filing Date: January 25, 2005

For: METHODS FOR ISOLATING  
MONOCYTES

Customer No.: 20350

Confirmation No.

Examiner:

Technology Center/Art Unit:

SUBMISSION OF SUBSTITUTE  
SPECIFICATION AND  
COMMUNICATION UNDER 37 C.F.R.  
1.821-1.825

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith a Sequence Listing in paper and computer readable forms.

Prior to examination of the above-referenced application, please enter the following amendments and remarks:

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.

**Amendments to the Specification:**

Please amend the title as follows:

"~~METHOD OF~~ METHODS FOR ISOLATING MONOCYTES"

Please replace the specification with the accompanying substitute specification. A marked up copy is provided showing the changes made.

Please cancel the present "SEQUENCE LISTING" at the end of the application (translation), and insert therefor the accompanying paper copy of the Sequence Listing.

**REMARKS/ARGUMENTS**

The Substitute Specification merely corrects typographical or clerical errors in the International Application and does not include new matter. In particular, the amendment to the title is made to more clearly reflect the subject matter of the instant application. Amendments to paragraphs [0031], [0035] and [0100] replace the misspelled word "isotopic" with "isotypic". Amendments to paragraphs [0037] and [0038] were made to correctly indicate the anti-mHIDE1 antibody. The amendment to paragraph [0046] merely corrects an oversight made when preparing the Japanese text. The amendment to paragraph [0112] was made to more clearly describe the procedure performed. The amendments to paragraphs [0037], [0038], [0046] and [0112] are obvious to one of skill in the art and in light of the rest of the specification. The amendment to paragraph [0117] was made to correct a typographical error. No new matter is added.

A Sequence Listing on paper and in computer readable form was prepared in accordance with 37 C.F.R. §§1.821 to 1.825, and is submitted herewith. The Sequence Listing does not include new matter or matter that goes beyond the disclosure of the International Application. The information contained in the computer readable disk was prepared through the use of the software program "FastSeq" and is identical to that of the paper copy of the Sequence Listing.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jennifer L. Wahlsten  
Reg. No. 46,226

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments  
JLW:ath  
60830926 v1